Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial

JAMA

Volumn 279, Issue 19, 1998, Pages 1542-1547

  Catalona, William J ^a   Partin, Alan W ^b   Slawin, Kevin M ^c   Brawer, Michael K ^d   Flanigan, Robert C ^e   Patel, Anup ^f   Richie, Jerome P ^g   DeKernion, Jean B ^f   Walsh, Patrick C ^b   Scardino, Peter T ^c   Lange, Paul H ^d   Subong, Eric N P ^b   Parson, Robert E ^h   Gasior, Gail H ^h   Loveland, Kathleen G ^h   Southwick, Paula C ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Hybritech Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; TUMOR VOLUME;

EID: 0032550630     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.19.1542     Document Type: Article

References (37)

1. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
2. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990;194:755-763.
3. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem. 1991;37:1618-1625.
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222-226.
5. Christensson A, Bjork T, Nilsson O, et al. Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-105.
6. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA and pathologic features of prostatic carcinomas. J Urol. 1996;155(suppl):415.
7. Carter HB, Partin AW, Luderer AA, et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 1997;49:379-384.
8. Arcangeli CG, Humphrey PA, Smith DS, et al. Percentage of free prostate specific antigen in serum as a predictor of pathological features of prostate cancer. Urology. In press.
9. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free PSA for staging of men with clinically localized prostate cancer. J Urol. 1998;159:1238-1242.
10. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214-1220.
11. Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996;48(suppl):55-61.
12. Luderer AA, Chen Y, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995;46:187-194.
13. Vashi AR, Wojno KJ, Henricks W, et al. Determination of the "reflex range" and appropriate cut-points for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 1997;49:19-27.
14. Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, Baert LV. Free-to-total prostate-specific antigen ratio as a single test for detection of significant stage Tie prostate cancer. J Urol. 1996;156:1042-1049.
15. Van Cangh PJ, De Nayer P, Sauvage P, et al. Free-to-total prostate-specific antigen (PSA) ratio is superior to total PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate. 1996;7(suppl):30-34.
16. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology. 1996;47:518-524.
17. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1998;159:5-12.
18. Woodrum DL, French C, Shamel LB. Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions. Urology. 1996;48(suppl):33-39.
19. Woodrum DL, French CF, Hill TM, et al. Analytical performance of the Tandem®-R free PSA immuno-assay measuring free prostate-specific antigen. Clin Chem. 1997;43:1203-1208.
20. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989.
21. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate-specific antigen values. J Urol. 1994; 151:1571-1574.
22. Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans. Philadelphia, Pa: Society for Industrial and Applied Mathematics; 1982.
23. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1993;82:171-185.
24. Littrup PJ, Goodman AC. Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction. Cancer. 1995;75(suppl): 1987-1993.
25. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309-1315.
26. Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst. 1996;88:1706-1707.
27. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452-1455.
28. Van Cangh PJ, De Nayer P, de Vischer L, et al. Free-to-total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology. 1996;48(suppl):67-70.
29. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995;154:1090-1095.
30. Pearson JD, Partin AW, Chan DW, Luderer AA, Carter HB. Serial measurements of serum total PSA, free PSA, and free/total PSA ratio in men with and without prostate disease. J Urol. 1996;155 (suppl):606.
31. Carter HB, Pearson JD, Metter JE, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
32. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273:289-294.
33. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol. 1997;157:544-547.
34. Lerner SE, Jacobsen SJ, Lilja H, et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology. 1996;48:240-248.
35. Chan DW, Sokoll LJ, Jones KA, Kelley CA, Subong ENP, Partin AW. Clinical evaluation of two free PSA assays in combination with different total PSA assays. J Urol. 1997;157(suppl):112.
36. Fortunato A, Dorizzi RM, Marchi G, Cocco C, Davini A. fPSA/tPSA ratios obtained using nine commercial assays. Clin Chem. 1996;42(suppl):268.
37. Jung K, Stephan C, Lein M, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 1996;42:1026-1033.